Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus.
Toxoplasmic encephalitis (TE) is the second most common AIDS-related opportunistic infection of the CNS. It occurs in 10%-50% of patients with AIDS who are seropositive for antibodies to Toxoplasma gondii and have CD4+ T lymphocyte counts of < 100/mm3. Primary toxoplasmic infection usually is acquired by ingestion of T. gondii oocysts from soil contaminated by cat feces or by ingestion of tissue cysts present in undercooked red meats. In patients with AIDS, TE probably results from the reactivation of Toxoplasma tissue cysts that remained latent after the primary infection. Detection of IgG antibodies to Toxoplasma indicates prior infection and the possible presence of tissue cysts and, thus, risk for developing TE. A regimen of trimethoprim-sulfamethoxazole or dapsone plus pyrimethamine with leucovorin is recommended for persons infected with the human immunodeficiency virus (HIV) and who are seropositive for IgG to Toxoplasma after their CD4+ T lymphocyte counts fall to < 100/mm3. HIV-infected persons who are seronegative for IgG to Toxoplasma should be counseled to protect themselves from primary toxoplasmic infection by eating only well-cooked meats and washing their hands after outdoor activities involving soil contact; if they have a cat, they should feed it only commercial or well-cooked foods, keep it indoors, and make sure that the litter box is changed daily. HIV-infected persons who are Toxoplasma seropositive may also be advised about these preventive behavioral practices.
Division of Parasitic Diseases, Centers for Disease Control and Prevention, CDC, Atlanta, Georgia 30333, USA.
F O
FO
Richards
J A
JA
Kovacs
B J
BJ
Luft
D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology / Q000517:prevention & control*; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002415:Cats; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004660:Encephalitis / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D002955:Leucovorin / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D012008:Recurrence; D012307:Risk Factors; D014124:Toxoplasmosis, Animal / Q000453:epidemiology; D016781:Toxoplasmosis, Cerebral / Q000453:epidemiology / Q000517:prevention & control*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D002955:Leucovorin; D011739:Pyrimethamine